Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
NEJM 388:511-517, Kin,B.S.,et al, 2023
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy
JAMA Neurol 76:827-833, Morales, D.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013
Erythromelalgia? A Clinical Study of People Who Experience Red, Hot, Painful Feet in the Community
Int J Vasc Med ID=864961, Friberg, D.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Evidence-based guideline: Treatment of painful diabetic neuropathy
Neurol 76:1758-1765, Bril,V., et al, 2011
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Causative Factors and Epidemiology of Bilateral Vestibulopathy in 255 Patients
Ann Neurol 61:524-532, Zingler,V.C.,et al, 2007
Linezolid-Associated Toxic Optic Neuropathy
Neurol 66:595-598, Rucker,J.C.,et al, 2006
Neuropathy Resembling CIDP in Patients Receiving Tumor Necrosis Factor-a Blockers
Neurol 64:1468-1470, Richez,C.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
JAMA 294:2744-2750, Sejvar,J.J.,et al, 2005
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
JAMA 294:2720-2725, Izurieta,H.S.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Vasculitic Mononeuritis Multiplex Induced by Valcyclovir
Neurol 62:1906-1907, Pary,L.F.,et al, 2004
Guillain-Barre Syndrome Seen in Users of Isotretinoin
BMJ 328:1537, Pritchard,J.,et al, 2004
Thalidomide Sensory Neurotoxicity
Neurol 62:2291-2293, Cavaletti,G.,et al, 2004
Guillain-Barre Syndrome Follwoing Influenza Vaccination
JAMA 292:2478-2481, Haber,P.,et al, 2004
Clinicopath Conf., Colchicine Myoneuropathy
NEJM 349:1656-1663, Case 33-2003, 2003
Disopyramide-induced Neuropathy
Neurol 58:663, Briani,C.,et al, 2002
Statins and Risk of Polyneuropathy
Neurol 58:1333-1337,1321, Gaist,D.,et al, 2002
Thalidomide-Induced Neuropathy
Neurol 59:1872-1875, Chaudhry,V.,et al, 2002
Clumsiness, Confusion, Coma, and Valproate
Lancet 353:1408, Ellaway,C.J.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Amantadine-Induced Peripheral Neuropathy
Neurol 53:1862-1865, Shulman,L.M.,et al, 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Evaluation of Metronidazole Toxicity: A Prospective Study
Int J Clin Pharmacol Res 19:83-88, Kapoor,K.,et al, 1999
Lhermitte's Sign Following Chemotherapy with Docetaxel
Neurol 50:563-564, van den Bent,M.J.,et al, 1998
Chloroquine Myopathy and Neuropathy with Elevated CSF Protein
Neurol 51:1226-1227, Wasay,M.,et al, 1998
Pulse Cyclophosphamide Therapy in Chronic Inflammatory Demyelinating Polyneuropathy
Neurol 51:1735-1738, Good,J.L.,et al, 1998
Self-Reported Exposure to Neurotoxic Chemical Combinations in the Gulf War:A Cross-Sectional Epidemiologic Study
JAMA 227:231-237, 2591997., Haley,R.W.&Kurt,T.L., 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Cost Effectiveness of Oral Compared with IV Antibiotic Therapy for Pts with Early Lyme Dis or Lyme Arthritis
NEJM 337:357-363, Eckman,M.H.,et al, 1997